CN104547325A - Medicinal composition for treating chronic idiopathic urticaria and application thereof - Google Patents
Medicinal composition for treating chronic idiopathic urticaria and application thereof Download PDFInfo
- Publication number
- CN104547325A CN104547325A CN201510029390.XA CN201510029390A CN104547325A CN 104547325 A CN104547325 A CN 104547325A CN 201510029390 A CN201510029390 A CN 201510029390A CN 104547325 A CN104547325 A CN 104547325A
- Authority
- CN
- China
- Prior art keywords
- chronic idiopathic
- idiopathic urticaria
- treatment
- pharmaceutical composition
- medicinal composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a medicinal composition for treating chronic idiopathic urticaria and application thereof. The medicinal composition is prepared by extracting Chinese medicinal raw materials with 70-72% (by volume) ethanol. The medicinal composition is characterized in that the Chinese medicinal raw materials comprise cushaw stems, Chinese dodder seeds, cottonrose hibiscus flowers and common ducksmeat herb. The medicinal composition can achieve a total effective rate of 92.8% when being used for treating the clinical symptoms of chronic idiopathic urticaria, is capable of relieving and eliminating clinical symptoms such as wheal and itching effectively, and has few side effects and high security.
Description
Technical field
The invention belongs to technical field of Chinese medicine, be specifically related to a kind of pharmaceutical composition and application thereof for the treatment of chronic idiopathic urticaria.
Background technology
Chronic idiopathic urticaria (chronic idiopathic urticaria, CIU) belongs to a kind of comparatively common cutaneous diseases, shows as pruritus and recurrent exerbation.Its cause of disease and pathogenesis complexity, Most patients can not find pathogenic factor, and research proves that the humoral immunization that the pathogenesis of urticaria not only has IgE to mediate participates in, and also has the participation of cellular immunization.Modern medicine thinks that urticaria is under many factors effect, causes a kind of localized edema that skin, mucosa, thin vessels are expanded and permeability increases and occurs to react.At present, it is Desloratadine that clinical treatment chronic urticaria mainly uses, and it is the antihistamine drug of the second filial generation, has H 2 receptor affinity of height, simultaneously through stablizing the effect of mast cell membrane, can discharge to stop the Mediators of inflammation such as 5-hydroxy tryptamine, histamine; Moreover, can also stop eosinophilic granulocyte move towards the position of inflammation [, have certain curative effect to chronic urticaria, but curative effect is not ideal enough, and has certain xerostomia, the side effect such as weak, dizzy.In view of patient often worry Western medicine untoward reaction and turn choose medical treatment, therefore research and development of new treatment chronic idiopathic urticaria Chinese patent medicine seem necessary.
Summary of the invention
In view of the deficiencies in the prior art, the object of the invention is to by furtheing investigate further secret prescription handed down in the family from generation to generation, a kind of pharmaceutical composition and application thereof for the treatment of chronic idiopathic urticaria are provided.
The object of the present invention is achieved like this:
Treat a pharmaceutical composition for chronic idiopathic urticaria, this pharmaceutical composition is by traditional Chinese medicinal material raw materials through being that 70-72% ethanol extraction forms through volumetric concentration, and described traditional Chinese medicinal material raw materials is made up of Semen Celosiae Cristatae, Fructus Xanthii and Herba Tripterospermi.Preferably, the pharmaceutical composition for the treatment of chronic idiopathic urticaria as above, the amount ratio of wherein each raw material is: Caulis Cucurbitae 40-60 part, Semen Cuscutae 9-15 part, Flos Hibisci Mutabilis 3-6 part, Herba Spirodelae 7-13 part.Further preferably, the pharmaceutical composition for the treatment of chronic idiopathic urticaria as above, the amount ratio of wherein each raw material is: Caulis Cucurbitae 46-55 part, Semen Cuscutae 11-13 part, Flos Hibisci Mutabilis 4-5.2 part, Herba Spirodelae 9-11 part.In a most institute preferred embodiment of the present invention, the pharmaceutical composition for the treatment of chronic idiopathic urticaria as above, the amount ratio of wherein each raw material is: Caulis Cucurbitae 50 parts, Semen Cuscutae 12 parts, Flos Hibisci Mutabilis 5 parts, 10 parts, Herba Spirodelae.
It should be noted that, medicinal raw material of the present invention has following source: Caulis Cucurbitae selects the dry stem of cucurbitaceous plant Fructus Cucurbitae moschatae Cucurbita moschata (Duch. Ex Lam.) Duch. Ex Poir..Semen Cuscutae selects the dry mature seed of convolvulus cuscuta plant Cuscuta chinensis Lam..Flos Hibisci Mutabilis selects the dry flower of Malvaceae plant Hibisci Mutabilis Hibiscus mutabilis L..Herba Spirodelae selects the dry herb of plant and of its applications duckweed Spirodela polyrrhiza (L.) Schleid..
In addition, using pharmaceutical composition of the present invention as the Chinese medicine granules of active component, the therapeutic effect of the Patients with Chronic Idiopathic Urticaria of clinical definite is shown, its clinical efficacy is remarkable, obvious treatment than application Desloratadine takes advantage, effectively can alleviate and eliminate the clinical symptoms such as welt, pruritus, improve the quality of life of patient, adverse effect is less.Based on this result of the test, another object of the present invention is to provide a kind of pharmaceutical applications, that is: the application of above-mentioned pharmaceutical composition in the medicine of preparation treatment chronic idiopathic urticaria.In institute of the present invention preferred embodiment, the medicine for the treatment of chronic idiopathic urticaria as above is oral formulations, and described oral formulations is granule, capsule, tablet, oral liquid.
Compared with prior art, after medicine composite for curing of the present invention, clinical symptoms total effective rate reaches 92.8%, effectively can alleviate and eliminate the clinical symptoms such as welt, pruritus, and drug side effect is little simultaneously, and safety is high.
Detailed description of the invention
Be below concrete preparation example and the effect test example of pharmaceutical composition involved in the present invention and solid orally ingestible, technical scheme of the present invention and technique effect are done and describes further, but protection scope of the present invention be not limited to following examples.
the preparation of embodiment 1 extract dry powder
Take Caulis Cucurbitae 5kg, Semen Cuscutae 1.2kg, Flos Hibisci Mutabilis 0.5kg, Herba Spirodelae 1kg, be placed in the reflux, extract, device with round-bottomed flask, add the alcoholic solution that 10L volumetric concentration is 70%, heating and refluxing extraction 3 times, each backflow 2h, 4 layers of filtered through gauze, merging filtrate; Filtrate is through concentrating under reduced pressure and to thick paste after reclaiming ethanol, and lyophilization, is ground into fine powder, crosses 100 mesh sieves, obtains extract dry powder.
the preparation of embodiment 2 Chinese medicine granules
Using the extract dry powder of embodiment 1 preparation as raw material, add other adjuvant and prepare granule, concrete formulation and technology is as follows:
Extract dry powder 50g
Dextrin 200g
Mannitol 80g
Icing Sugar 200g
Aspartame 0.3g
Preparation method: take stock and adjunct by above-mentioned prescription, 100 mesh sieves crossed by raw material, and 80 mesh sieves crossed by adjuvant, and then by supplementary material mix homogeneously, adopt dry granulating machine to granulate, 20 order granulate, carry out subpackage by often wrapping 10g.
clinical practice example
Patient 56 example of chronic idiopathic urticaria, all meet the diagnostic criteria about chronic idiopathic urticaria in " clinical dermatology ", man has 34 examples, female has 22 examples, age was at 27 ~ 59 years old, the median age is (37.5 ± 2.0) year, private prosecution pruritus, get rid of intentionally hepatic and kidney function obstacle, malignant tumor, systemic disease, disease in the blood system, trimester of pregnancy, the patient of age of sucking, all without accepting triazole antifungal agent, macrolide antibiotics is treated, without the Drug therapy accepting glucocorticoid medicine treatment or other treatment urticaria in nearly 1 month.
All cases are divided into test group and matched group at random, are respectively 28 examples, observe contrast two groups of clinical symptoms curative effects, rate of adverse reactions.Two groups of patients carry out contrasting all not statistically significants from the aspect of age, sex, have comparability.After on-test, matched group patient adopts Desloratadine to treat, and oral Desloratadine sheet (trade name: cottonrose hibiscus must be stung, Hainan Pulin Pharmaceutical Co., Ltd produces), 5mg/d, 1 day 1 time, treatment 4 weeks is 1 course for the treatment of continuously.The Chinese medicine granules treatment that test group adopts above-described embodiment 2 to prepare, 1 time/d, each 1 bag, treatment 4 weeks is 1 course for the treatment of continuously.
Take medicine after terminating and carry out clinical symptoms therapeutic evaluation, evaluation content comprises carries out level Four scoring according to the scoring of welt number, maximum welt diameter, pruritus degree to clinical symptoms, sign, specific as follows: (1) welt number: to be 0 point without welt, 1 ~ 7 welt is 1 point, 8 ~ 14 welts are 2 points, and > 14 welts are 3 points.(2) maximum welt diameter: be 0 point without welt, maximum welt diameter < 0.5cm is 1 point, and maximum welt diameter is 2 points at 0.5 ~ 2.0cm, and maximum welt diameter > 2.0cm is 3 points.(3) pruritus degree: be 0 point without pruritus, slight pruritus, patient is 1 point without agitation, moderate pruritus, but still to stand be 2 points, and serious pruritus, it is 3 points that patient cannot stand.Before foundation treatment, rear 4 weeks situations of following up a case by regular visits to are marked with treatment, judge: integration × 100% before integration decline index=(integration after the integration-treatment before treatment)/treatment according to following formula to curative effect.Recovery from illness: clinical symptoms and sign disappear all completely; Effective: the integration decline index of symptom is more than 70%; Effective: the integration decline index of symptom is in 30% ~ 70% scope; Invalid: the integration decline index of symptom is within 30%.Total obvious effective rate=(curing number of cases+effective number of cases)/total number of cases × 100%.
Can be found out by the clinical symptoms efficacy result of table 1, the total obvious effective rate of matched group is 67.8%, and the total obvious effective rate of test group is 92.8%; Test group is obviously better than the curative effect of matched group, and the clinical symptoms curative effect of two groups of patients compares exists the significance difference opposite sex.
The table 1 liang group clinical symptoms comparitive study for the treatment of after 4 weeks [n (%)]
| Group | Number of cases | Recovery from illness | Effective | Effectively | Invalid | Total obvious effective rate (%) |
| Matched group | 28 | 9（32.1） | 10（35.7） | 4（14.3） | 5（17.9） | 67.8 |
| Test group | 28 | 16（57.1） | 10（35.7） | 2（7.2） | 0（0） | 92.8 |
In addition, occur 2 examples of feeling sick during treatment of control group, xerostomia 2 example, weak 1 example, dizzy 1 example, adverse reaction rate is 10.7%; And test group treatments period occurs only having 1 example to occur giddy.
Claims (6)
1. treat a pharmaceutical composition for chronic idiopathic urticaria, this pharmaceutical composition is that 70-72% ethanol extraction forms by traditional Chinese medicinal material raw materials through volumetric concentration, and it is characterized in that, described traditional Chinese medicinal material raw materials is made up of Caulis Cucurbitae, Semen Cuscutae, Flos Hibisci Mutabilis and Herba Spirodelae.
2. the pharmaceutical composition for the treatment of chronic idiopathic urticaria according to claim 1, is characterized in that, the amount ratio of each raw material is: Caulis Cucurbitae 40-60 part, Semen Cuscutae 9-15 part, Flos Hibisci Mutabilis 3-6 part, Herba Spirodelae 7-13 part.
3. the pharmaceutical composition for the treatment of chronic idiopathic urticaria according to claim 2, is characterized in that, the amount ratio of each raw material is: Caulis Cucurbitae 46-55 part, Semen Cuscutae 11-13 part, Flos Hibisci Mutabilis 4-5.2 part, Herba Spirodelae 9-11 part.
4. the pharmaceutical composition for the treatment of chronic idiopathic urticaria according to claim 3, is characterized in that, the amount ratio of each raw material is: Caulis Cucurbitae 50 parts, Semen Cuscutae 12 parts, Flos Hibisci Mutabilis 5 parts, 10 parts, Herba Spirodelae.
5. the application of the pharmaceutical composition described in any one of claim 1-4 in the medicine of preparation treatment chronic idiopathic urticaria.
6. application according to claim 5, is characterized in that, described medicine is oral formulations, and described oral formulations is granule, capsule, tablet, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510029390.XA CN104547325A (en) | 2015-01-21 | 2015-01-21 | Medicinal composition for treating chronic idiopathic urticaria and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510029390.XA CN104547325A (en) | 2015-01-21 | 2015-01-21 | Medicinal composition for treating chronic idiopathic urticaria and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104547325A true CN104547325A (en) | 2015-04-29 |
Family
ID=53065096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510029390.XA Pending CN104547325A (en) | 2015-01-21 | 2015-01-21 | Medicinal composition for treating chronic idiopathic urticaria and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104547325A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112203724A (en) * | 2018-03-26 | 2021-01-08 | 诺华股份有限公司 | Methods of treating chronic idiopathic urticaria using Rigeuzumab |
| CN116514911A (en) * | 2023-04-20 | 2023-08-01 | 永创恒新生物医学科技(北京)有限公司 | Polypeptide and application thereof in preparation of medicines for treating chronic urticaria |
-
2015
- 2015-01-21 CN CN201510029390.XA patent/CN104547325A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112203724A (en) * | 2018-03-26 | 2021-01-08 | 诺华股份有限公司 | Methods of treating chronic idiopathic urticaria using Rigeuzumab |
| CN116514911A (en) * | 2023-04-20 | 2023-08-01 | 永创恒新生物医学科技(北京)有限公司 | Polypeptide and application thereof in preparation of medicines for treating chronic urticaria |
| CN116514911B (en) * | 2023-04-20 | 2024-02-27 | 无锡观合医学检验所有限公司 | Polypeptide and application thereof in preparation of medicines for treating chronic urticaria |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1325083C (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN103830632A (en) | Chinese traditional medicine preparation for radically treating psoriasis and multiple skin diseases and preparation method and application thereof | |
| CN105168385B (en) | A kind of pharmaceutical composition of anti-bacterial, anti-itching and preparation method thereof | |
| CN103070963A (en) | Traditional Chinese medicine preparation for treating candida albicans infection diseases | |
| CN102552769A (en) | Medicine for treating vaginitis and preparation method thereof | |
| CN103272092A (en) | Huoxiang Zhengqi externally-applied preparation and its preparation method and application | |
| CN101474192A (en) | Veramyst medicinal preparation and preparation method | |
| CN103169831B (en) | Traditional Chinese medicine composition for treating dysmenorrhea and preparation method thereof | |
| CN105326908A (en) | Medicine composition for treating rhinitis and application thereof | |
| CN104547325A (en) | Medicinal composition for treating chronic idiopathic urticaria and application thereof | |
| CN102240353A (en) | Traditional Chinese drug anesthetic and preparation method thereof | |
| CN102210773B (en) | Chinese medicinal cataplasm for treating infantile pneumonia, preparation method thereof and application thereof | |
| CN101502608A (en) | Chinese paris rhizome total sapogenin oral medication preparation as well as preparation method and application thereof | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN100423735C (en) | Traditional Chinese medicine for treating haemorrhoids | |
| CN102284036A (en) | Gujinwan capsule and preparation method thereof | |
| CN101991664B (en) | Gel agent for treating acnes and preparation method thereof | |
| CN101879227B (en) | Chinese medicinal composition for treating protrusion of lumbar intervertebral disci and preparation method thereof | |
| CN1294958C (en) | Chinese medicinal preparation for treating acne and production thereof | |
| CN106983822A (en) | It is a kind of to treat Chinese medicine composition of vaginitis and its preparation method and application | |
| CN101234140A (en) | Pharmaceutical composition for curing eczema and preparation and application thereof | |
| CN105412419A (en) | Terbinafine hydrochloride compound vagina slow-release effervescent tablets and preparation method | |
| CN105106561A (en) | Miconazole nitrate compound vaginal extended-release effervescent tablets and preparation method thereof | |
| CN103877425A (en) | Chinese medicinal composition as well as preparation method and application thereof | |
| CN103784539B (en) | One is treated psoriatic Chinese medicine composition and preparation and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150429 |
|
| WD01 | Invention patent application deemed withdrawn after publication |